REFERENCES
1. EDMONDSON HA. Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood. AMA J Dis Child 1956;91:168-86.
2. Lafaro KJ, Pawlik TM. Fibrolamellar hepatocellular carcinoma: current clinical perspectives. J Hepatocell Carcinoma 2015;2:151-7.
3. Craig JR, Peters RL, Edmondson HA, Omata M. Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features. Cancer 1980;46:372-9.
4. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. No. Ed. 4. World Health Organization. 2010;
5. Lim II, Farber BA, LaQuaglia MP. Advances in fibrolamellar hepatocellular carcinoma: a review. Eur J Pediatr Surg 2014;24:461-6.
6. El-Serag HB, Davila JA. Is fibrolamellar carcinoma different from hepatocellular carcinoma? Hepatology 2004;39:798-803.
7. Graham RP. Fibrolamellar carcinoma: what is new and why it matters. Surg Pathol Clin 2018;11:377-87.
8. Eggert T, McGlynn KA, Duffy A, Manns MP, Greten TF, Altekruse SF. Fibrolamellar hepatocellular carcinoma in the USA, 2000-2010: a detailed report on frequency, treatment and outcome based on the surveillance, epidemiology, and end results database. United European Gastroenterol J 2013;1:351-7.
9. Ramai D, Ofosu A, Lai JK, Gao ZH, Adler DG. Fibrolamellar hepatocellular carcinoma: a population-based observational study. Dig Dis Sci 2021;66:308-14.
10. Perisetti A, Goyal H, Yendala R, Thandassery RB, Giorgakis E. Non-cirrhotic hepatocellular carcinoma in chronic viral hepatitis: current insights and advancements. World J Gastroenterol 2021;27:3466-82.
11. Houben KW, McCall JL. Liver transplantation for hepatocellular carcinoma in patients without underlying liver disease: a systematic review. Liver Transpl Surg 1999;5:91-5.
12. Liu S, Wah Chan K, Tong J, Wang Y, Wang B, Qiao L. PET-CT scan is a valuable modality in the diagnosis of fibrolamellar hepatocellular carcinoma: a case report and a summary of recent literature. QJM 2011;104:477-83.
13. Haratake J, Horie A, Lee SD, Huh MH. Fibrolamellar carcinoma of the liver in a middle-aged Korean man. J UOEH 1990;12:349-54.
14. Hoshino H, Katada N, Nishimura D, et al. Case report: fibrolamellar hepatocellular carcinoma in a Japanese woman: a case report and review of Japanese cases. J Gastroenterol Hepatol 1996;11:551-5.
15. Assi H, Hatoum H, Mukherjee S, Machiorlatti M, Vesely S, Pareek V. Clinical characteristics and predictors of outcomes in patients with fibrolamellar carcinoma: an eleven-year analysis of the National Cancer Database (NCDB). JCO 2019;37:413-413.
16. Chakrabarti S, Tella SH, Kommalapati A, et al. Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma. J Gastrointest Oncol 2019;10:554-61.
17. Wahab MA, El Hanafy E, El Nakeeb A, Ali MA. Clinicopathological features and surgical outcome of patients with fibrolamellar hepatocellular carcinoma (experience with 22 patients over a 15-year period). World J Gastrointest Surg 2017;9:61-7.
18. Andersen JB. Fibrolamellar hepatocellular carcinoma: a rare but distinct type of liver cancer. Gastroenterology 2015;148:707-10.
19. Chapuy CI, Sahai I, Sharma R, Zhu AX, Kozyreva ON. Hyperammonemic encephalopathy associated with fibrolamellar hepatocellular carcinoma: case report, literature review, and proposed treatment algorithm. Oncologist 2016;21:514-20.
20. Muramori K, Taguchi S, Taguchi T, et al. High aromatase activity and overexpression of epidermal growth factor receptor in fibrolamellar hepatocellular carcinoma in a child. J Pediatr Hematol Oncol 2011;33:e195-7.
21. McDonald JD, Gupta S, Shindorf ML, et al. Elevated serum α-fetoprotein is associated with abbreviated survival for patients with fibrolamellar hepatocellular carcinoma who undergo a curative resection. Ann Surg Oncol 2020;27:1900-5.
22. Ang CS, Kelley RK, Choti MA, et al. Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium. Gastrointest Cancer Res 2013;6:3-9.
23. Yamashita S, Vauthey JN, Kaseb AO, et al. Prognosis of fibrolamellar carcinoma compared to non-cirrhotic conventional hepatocellular carcinoma. J Gastrointest Surg 2016;20:1725-31.
25. Morise Z, Sugioka A, Mizoguchi Y, et al. Fibrolamellar carcinoma of the liver in a Japanese hepatitis B virus carrier. J Gastroenterol Hepatol 2005;20:1136-8.
26. Dadke D, Jaganath P, Krishnamurthy S, Chiplunkar S. The detection of HBV antigens and HBx-transcripts in an Indian fibrolamellar carcinoma patient: a case study. Liver 2002;22:87-91.
27. Chaudhari VA, Khobragade K, Bhandare M, Shrikhande SV. Management of fibrolamellar hepatocellular carcinoma. Chin Clin Oncol 2018;7:51.
28. Ganeshan D, Szklaruk J, Kundra V, Kaseb A, Rashid A, Elsayes KM. Imaging features of fibrolamellar hepatocellular carcinoma. AJR Am J Roentgenol 2014;202:544-52.
29. Lin CC, Yang HM. Fibrolamellar carcinoma: a concise review. Arch Pathol Lab Med 2018;142:1141-5.
30. Stipa F, Yoon SS, Liau KH, et al. Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer 2006;106:1331-8.
31. Lildballe DL, Nguyen KQ, Poulsen SS, Nielsen HO, Nexo E. Haptocorrin as marker of disease progression in fibrolamellar hepatocellular carcinoma. Eur J Surg Oncol 2011;37:72-9.
32. Fu T, Ding H, Xu C, Zhu Y, Xue L, Lin F. Imaging findings of fibrolamellar hepatocellular carcinomas on ultrasonography: a comparison with conventional hepatocellular carcinomas. Clin Hemorheol Microcirc 2021;77:49-60.
33. Dong Y, Wang WP, Mao F, et al. Imaging features of fibrolamellar hepatocellular carcinoma with contrast-enhanced ultrasound. Ultraschall Med 2021;42:306-13.
34. Ichikawa T, Federle MP, Grazioli L, Madariaga J, Nalesnik M, Marsh W. Fibrolamellar hepatocellular carcinoma: imaging and pathologic findings in 31 recent cases. Radiology 1999;213:352-61.
35. Ganeshan D, Szklaruk J, Kaseb A, Kattan A, Elsayes KM. Fibrolamellar hepatocellular carcinoma: multiphasic CT features of the primary tumor on pre-therapy CT and pattern of distant metastases. Abdom Radiol (NY) 2018;43:3340-8.
36. Liu S, Chan KW, Wang B, Qiao L. Fibrolamellar hepatocellular carcinoma. Am J Gastroenterol 2009;104:2617-24; quiz 2625.
37. O'Neill AF, Church AJ, Perez-Atayde AR, Shaikh R, Marcus KJ, Vakili K. Fibrolamellar carcinoma: an entity all its own. Curr Probl Cancer 2021;45:100770.
38. Ward SC, Huang J, Tickoo SK, Thung SN, Ladanyi M, Klimstra DS. Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation. Mod Pathol 2010;23:1180-90.
39. Honeyman JN, Simon EP, Robine N, et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science 2014;343:1010-4.
40. Riggle KM, Turnham R, Scott JD, Yeung RS, Riehle KJ. Fibrolamellar hepatocellular carcinoma: mechanistic distinction from adult hepatocellular carcinoma. Pediatr Blood Cancer 2016;63:1163-7.
41. Oliveira S, Houseright RA, Korte BG, Huttenlocher A. DnaJ-PKAc fusion induces liver inflammation in a zebrafish model of fibrolamellar carcinoma. Dis Model Mech 2020;13:dmm042564.
42. Kakar S, Chen X, Ho C, et al. Chromosomal changes in fibrolamellar hepatocellular carcinoma detected by array comparative genomic hybridization. Mod Pathol 2009;22:134-41.
43. Vyas M, Hechtman JF, Zhang Y, et al. DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma. Mod Pathol 2020;33:648-56.
44. Graham RP, Yeh MM, Lam-Himlin D, et al. Molecular testing for the clinical diagnosis of fibrolamellar carcinoma. Mod Pathol 2018;31:141-9.
45. Lemekhova A, Hornuss D, Polychronidis G, et al. Clinical features and surgical outcomes of fibrolamellar hepatocellular carcinoma: retrospective analysis of a single-center experience. World J Surg Oncol 2020;18:93.
46. Schlageter M, Terracciano LM, D’Angelo S, Sorrentino P. Histopathology of hepatocellular carcinoma. World J Gastroenterol 2014;20:15955-64.
47. Ashtari S, Pourhoseingholi MA, Sharifian A, Zali MR. Hepatocellular carcinoma in Asia: prevention strategy and planning. World J Hepatol 2015;7:1708-17.
48. Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017;11:317-70.
49. Ozakyol A. Global epidemiology of hepatocellular carcinoma (HCC Epidemiology). J Gastrointest Cancer 2017;48:238-40.
50. Zhu RX, Seto WK, Lai CL, Yuen MF. Epidemiology of hepatocellular carcinoma in the Asia-Pacific region. Gut Liver 2016;10:332-9.
51. Kennedy K, Graham SM, Arora N, Shuhart MC, Kim HN. Hepatocellular carcinoma among US and non-US-born patients with chronic hepatitis B: risk factors and age at diagnosis. PLoS One 2018;13:e0204031.
52. Attwa MH, El-Etreby SA. Guide for diagnosis and treatment of hepatocellular carcinoma. World J Hepatol 2015;7:1632-51.
53. Balogh J, Victor D 3rd, Asham EH, et al. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma 2016;3:41-53.
54. Roberts LR, Sirlin CB, Zaiem F, et al. Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatology 2018;67:401-21.[PMID:28859233 DOI:10.1002/hep.29487]
55. Lim J, Singal AG. Surveillance and diagnosis of hepatocellular carcinoma. Clin Liver Dis (Hoboken) 2019;13:2-5.
56. Sherman CB. Utilization and accuracy of biopsy in patients with hepatocellular carcinoma in a community based setting. J Clin Gastroenterol Treat 2016:2.
57. Bajenaru N, Balaban V, Săvulescu F, Campeanu I, Patrascu T. Hepatic hemangioma -review-. J Med Life 2015;8:4-11.
58. Kim KW, Kim TK, Han JK, et al. Hepatic hemangiomas: spectrum of US appearances on gray-scale, power Doppler, and contrast-enhanced US. Korean J Radiol 2000;1:191-7.
59. Kim JM, Chung WJ, Jang BK, et al. Hemorrhagic hemangioma in the liver: a case report. World J Gastroenterol 2015;21:7326-30.
60. Hashemi J, Esmaeilzadeh A, DABAGH K V R, et al. Accuracy of gray-scale and color Doppler sonography in diagnosis of hepatic hemangioma, hepatocellular carcinoma and liver metastasis. IRANIAN JOURNAL OF RADIOLOGY 2008;5:129–34. Available from:https://www.sid.ir/en/journal/ViewPaper.aspx?id=116930[Last accessed on 11 May 2022].
61. Dietrich CF, Mertens JC, Braden B, Schuessler G, Ott M, Ignee A. Contrast-enhanced ultrasound of histologically proven liver hemangiomas. Hepatology 2007;45:1139-45.
62. Chan YL, Lee SF, Yu SC, Lai P, Ching AS. Hepatic malignant tumour versus cavernous haemangioma: differentiation on multiple breath-hold turbo spin-echo MRI sequences with different T2-weighting and T2-relaxation time measurements on a single slice multi-echo sequence. Clin Radiol 2002;57:250-7.
63. Mogahed MM, Zytoon AA, Essa B, Abdellatif W, Ghanem N, Elwakeel B. Natural history of hepatic hemangiomas as a guide for surgical indication. Egypt Liver Journal 2020:10.
64. Venturi A, Piscaglia F, Vidili G, et al. Diagnosis and management of hepatic focal nodular hyperplasia. J Ultrasound 2007;10:116-27.
65. Hsee LC, McCall JL, Koea JB. Focal nodular hyperplasia: what are the indications for resection? HPB (Oxford) 2005;7:298-302.
66. Roncalli M, Sciarra A, Tommaso LD. Benign hepatocellular nodules of healthy liver: focal nodular hyperplasia and hepatocellular adenoma. Clin Mol Hepatol 2016;22:199-211.
67. Bioulac-sage P. Les angiopoïétines : un rôle physiopathologique dans l’hyperplasie nodulaire focale. Gastroentérologie Clinique et Biologique 2004;28:200-1.
68. Burgio M, Ronot M, Salvaggio G, Vilgrain V, Brancatelli G. Imaging of hepatic focal nodular hyperplasia: pictorial review and diagnostic strategy. Semin Ultrasound CT MR 2016;37:511-24.
69. Shamsi K, De Schepper A, Degryse H, Deckers F. Focal nodular hyperplasia of the liver: radiologic findings. Abdom Imaging 1993;18:32-8.
70. Marin D, Brancatelli G, Federle MP, et al. Focal nodular hyperplasia: typical and atypical MRI findings with emphasis on the use of contrast media. Clin Radiol 2008;63:577-85.
71. Krause K, Tanabe KK. A shifting paradigm in diagnosis and management of hepatic adenoma. Ann Surg Oncol 2020;27:3330-8.
72. Vijay A, Elaffandi A, Khalaf H. Hepatocellular adenoma: an update. World J Hepatol 2015;7:2603-9.
73. Barthelmes L, Tait IS. Liver cell adenoma and liver cell adenomatosis. HPB (Oxford) 2005;7:186-96.
74. Grazioli L, Federle MP, Brancatelli G, Ichikawa T, Olivetti L, Blachar A. Hepatic adenomas: imaging and pathologic findings. Radiographics 2001;21:877-92; discussion 892.
75. Bieze M, van den Esschert JW, Nio CY, et al. Diagnostic accuracy of MRI in differentiating hepatocellular adenoma from focal nodular hyperplasia: prospective study of the additional value of gadoxetate disodium. AJR Am J Roentgenol 2012;199:26-34.
76. Nault JC, Bioulac-Sage P, Zucman-Rossi J. Hepatocellular benign tumors-from molecular classification to personalized clinical care. Gastroenterology 2013;144:888-902.
77. Horn SR, Stoltzfus KC, Lehrer EJ, et al. Epidemiology of liver metastases. Cancer Epidemiol 2020;67:101760.
78. Marx GM, Boyce A, Goldstein D. Elevated alpha-foetoprotein and hepatic metastases--it's not always what it seems! Ann Oncol 2002;13:167-9.
79. Chen Y, Qu H, Jian M, Sun G, He Q. High level of serum AFP is an independent negative prognostic factor in gastric cancer. Int J Biol Markers 2015;30:e387-93.
80. Karaosmanoglu AD, Onur MR, Ozmen MN, Akata D, Karcaaltincaba M. Magnetic resonance imaging of liver metastasis. Semin Ultrasound CT MR 2016;37:533-48.
81. Danet IM, Semelka RC, Leonardou P, et al. Spectrum of MRI appearances of untreated metastases of the liver. AJR Am J Roentgenol 2003;181:809-17.
82. Thian YL, Riddell AM, Koh DM. Liver-specific agents for contrast-enhanced MRI: role in oncological imaging. Cancer Imaging 2013;13:567-79.
84. Salgia R, Mendiratta V. The multidisciplinary management of hepatocellular carcinoma. Clin Liver Dis (Hoboken) 2021;17:405-8.
85. Mayo SC, Mavros MN, Nathan H, et al. Treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma: a national perspective. J Am Coll Surg 2014;218:196-205.
86. Mavros MN, Mayo SC, Hyder O, Pawlik TM. A systematic review: treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma. J Am Coll Surg 2012;215:820-30.
87. Pinna AD, Iwatsuki S, Lee RG, et al. Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation. Hepatology 1997;26:877-83.
88. Herman P, Chagas AL, Perini MV, et al. Surgical treatment of fibrolamellar hepatocellular carcinoma: an underestimated malignant tumor? Hepatobiliary & Pancreatic Diseases International 2014;13:618-21.
89. Atienza LG, Berger J, Mei X, et al. Liver transplantation for fibrolamellar hepatocellular carcinoma: a national perspective. J Surg Oncol 2017;115:319-23.
90. Njei B, Konjeti VR, Ditah I. Prognosis of patients with fibrolamellar hepatocellular carcinoma versus conventional hepatocellular carcinoma: a systematic review and Meta-analysis. Gastrointest Cancer Res 2014;7:49-54.
91. Ince V, Isik B, Ozdemir F, Ozgor D, Ara C, Yilmaz S. Living-Donor liver transplant for fibrolamellar hepatocellular carcinoma with hilar lymph node metastasis: a case report. Exp Clin Transplant 2018; doi: 10.6002/ect.2017.0040.
92. Mergental H, Adam R, Ericzon BG, et al. Liver transplantation for unresectable hepatocellular carcinoma in normal livers. J Hepatol 2012;57:297-305.
93. Gottlieb S, O'Grady C, Gliksberg A, Kent P. Early experiences with triple immunochemotherapy in adolescents and young adults with high-risk fibrolamellar carcinoma. Oncology 2021;99:310-7.
94. Kaseb AO, Shama M, Sahin IH, et al. Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma. Oncology 2013;85:197-203.
95. Lamarca A, Frizziero M, Fulton A, et al. Fibrolamellar carcinoma: challenging the challenge. Eur J Cancer 2020;137:144-7.
96. Patt YZ, Hassan MM, Lozano RD, et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol 2003;21:421-7.
97. Fonseca GM, Varella AD, Coelho FF, Abe ES, Dumarco RB, Herman P. Downstaging and resection after neoadjuvant therapy for fibrolamellar hepatocellular carcinoma. World J Gastrointest Surg 2014;6:107-11.
98. Braybrooke JP, Propper DJ, O'Byrne KJ, et al. Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha. Br J Cancer 2000;83:219-24.
99. Weeda VB, Murawski M, McCabe AJ, et al. Fibrolamellar variant of hepatocellular carcinoma does not have a better survival than conventional hepatocellular carcinoma--results and treatment recommendations from the childhood liver tumour strategy group (SIOPEL) experience. Eur J Cancer 2013;49:2698-704.
100. Katzenstein HM, Krailo MD, Malogolowkin MH, et al. Fibrolamellar hepatocellular carcinoma in children and adolescents. Cancer 2003;97:2006-12.
101. O’Neill A, Malogolowkin M, Brugieres L, et al. Gemcitabine and oxaliplatin for the treatment of pediatric patients with hepatocellular carcinoma. PEDIATRIC BLOOD & CANCER 2014;61:S128-9.
102. Abou-Alfa GK, Mayer R, Venook AP, et al. Phase II multicenter, open-label study of oral ENMD-2076 for the treatment of patients with advanced fibrolamellar carcinoma. Oncologist 2020;25:e1837-45.
103. El Dika I, Mayer RJ, Venook AP, et al. A multicenter randomized three-arm phase II study of (1) everolimus, (2) estrogen deprivation therapy (EDT) with leuprolide + letrozole, and (3) everolimus + EDT in patients with unresectable fibrolamellar carcinoma. Oncologist 2020;25:925-e1603.
104. Faivre S, Raymond E, Boucher E, et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. The Lancet Oncology 2009;10:794-800.
105. Mark Yarchoan. DNAJB1-PRKACA fusion kinase peptide vaccine combined with nivolumab and ipilimumab for patients with fibrolamellar hepatocellular carcinoma. Identifier NCT04248569. Available from:https://clinicaltrials.gov/ct2/show/NCT04248569[Last accessed on 11 May 2022].
106. Allison O’Neill. Checkpoint inhibition in pediatric hepatocellular carcinoma. Identifier NCT04134559. Available from:https://clinicaltrials.gov/ct2/show/NCT04134559?cond=Fibrolamellar+Carcinoma&draw=2&rank=9[Last accessed on 11 May 2022].
107. Tiao G. Cisplatin and combination chemotherapy in treating children and young adults with hepatoblastoma or liver cancer after surgery. Identifier NCT03533582. Available from: https://clinicaltrials.gov/ct2/show/NCT03533582?cond=Fibrolamellar+Carcinoma&draw=3&rank=11[Last accessed on 11 May 2022].
108. Aung Naing. Sapanisertib and Ziv-Aflibercept in treating patients with recurrent solid tumors that are metastatic or cannot be removed by surgery. Identifier NCT02159989. Available from: https://clinicaltrials.gov/ct2/show/NCT02159989?cond=Fibrolamellar+Carcinoma&draw=3&rank=12[Last accessed on 11 May 2022].
109. Peacock J, A Call J, R Olivier K. Radiotherapy for metastatic fibrolamellar hepatocellular carcinoma. Rare Tumors 2013;5:e28.
110. Epstein BE, Pajak TF, Haulk TL, Herpst JM, Order SE, Abrams RA. Metastatic nonresectable fibrolamellar hepatoma: prognostic features and natural history. Am J Clin Oncol 1999;22:22-8.
111. Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence. Cancer Treat Rev 2019;72:28-36.
112. Somma F, Stoia V, Serra N, D'Angelo R, Gatta G, Fiore F. Yttrium-90 trans-arterial radioembolization in advanced-stage HCC: the impact of portal vein thrombosis on survival. PLoS One 2019;14:e0216935.
113. Aryan M, Altshuler E, Qian X, Zhang W. Treatment of advanced hepatocellular carcinoma. Hepatocellular carcinoma - challenges and opportunities of a multidisciplinary approach. IntechOpen; 2021.
114. Whitlock RS, Loo C, Patel K, et al. Transarterial radioembolization treatment as a bridge to surgical resection in pediatric hepatocellular carcinoma. J Pediatr Hematol Oncol 2021;43:e1181-5.
115. Ljuboja D, Weinstein JL, Ahmed M, Sarwar A. Extrahepatic transarterial radioembolization to treat fibrolamellar hepatocellular carcinoma: a case report. Radiol Case Rep 2020;15:2613-6.
116. Mafeld S, French J, Tiniakos D, Haugk B, Manas D, Littler P. Fibrolamellar hepatocellular carcinoma: treatment with Yttrium-90 and subsequent surgical resection. Cardiovasc Intervent Radiol 2018;41:816-20.
117. Aguado A, Ristagno R, Towbin AJ, et al. Transarterial radioembolization with yttrium-90 of unresectable primary hepatic malignancy in children. Pediatr Blood Cancer 2019;66:e27510.
118. Grandhi MS, Pawlik TM. Managing fibrolamellar hepatocellular carcinoma. Expert Opinion on Orphan Drugs 2016;5:143-52.
119. Sergi C. Fibrolamellar carcinoma: a distinct variant of hepatocellular carcinoma that is still surrounded by unveils mysteries. JCT 2014;05:1325-31.
120. Arcement CM, Towbin RB, Meza MP, et al. Intrahepatic chemoembolization in unresectable pediatric liver malignancies. Pediatr Radiol 2000;30:779-85.
121. Spence RA, Rosen A, Krige JE, Blumgart RL, Temple-Camp CR, Terblanche J. Unresectable fibrolamellar hepatocellular carcinoma treated with intra-arterial lipiodolised doxorubicin-a case report. South African Medical Journal 1987;72:701-3.
